[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophageal-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophageal-neoplasms":34},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,50,80,110,139,161,194,216,243,274,298,320,352,376,409,434,453,480,509,531,553,577,600,625,652],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100601754","phase-1-a-study-of-ly4257496-in-participants-with-cancer-omniray-100601754",false,"NCT07114601","A Study of LY4257496 in Participants With Cancer (OMNIRAY)","A Phase 1a\u002Fb Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults With GRPR-Positive Advanced Solid Tumors (OMNIRAY)","OMNIRAY","Inclusion Criteria:\n\n* Must have histologically or cytologically proven diagnosis of locally advanced, unresectable, or metastatic cancer.\n* Must be assessed by computed tomography (CT)\u002Fmagnetic resonance imaging (MRI) to confirm at least 1 of the following:\n\n  * At least 1 measurable target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n  * If only bone lesions are present without a soft-tissue component, a bone scan or MRI must confirm at least 2 detectable lesions considered to represent active metastases\n* Must have GRPR-positive disease, defined by investigator assessment of GRPR imaging.\n* Must have the following histologically or cytologically confirmed diagnosis:\n\n  * Estrogen receptor (ER+)\u002Fhuman epidermal growth factor receptor 2 (HER2-) breast cancer\n  * ER+\u002FHER2+ breast cancer\n  * Esophageal squamous cell carcinoma\n  * Adenocarcinoma of the stomach, gastroesophageal junction, or esophagus\n  * Colorectal carcinoma\n  * Metastatic castration-resistant prostate cancer\n  * Endometrial carcinoma. Carcinosarcoma is eligible. Uterine leiomyosarcoma, adenosarcoma, or endometrial stromal sarcoma is not eligible.\n  * Low-grade papillary serous ovarian cancer\n  * Other non-Central Nervous System (CNS) primary GRPR-positive solid tumors (Cohorts A1 dose escalation and D1 dose expansion only)\n* For participants with breast cancer diagnosis, where possible, ER and HER2 status should be assessed from the most recent tissue biopsy taken at the time of presentation with recurrent or metastatic disease.\n\n  * To fulfill the requirement for ER+ disease by local testing, a tumor must express the ER immunohistochemistry, as defined in the relevant American Society of Clinical Oncology (ASCO)\u002FCollege of American Pathologists (CAP) guidelines.\n  * HER2 status should be determined by local testing, as defined in the relevant ASCO\u002FCAP Guidelines.\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1.\n* Must be able to comply with outpatient treatment, laboratory monitoring, imaging, and required clinic visits for the duration of trial participation.\n\nExclusion Criteria:\n\n* Phase 1a (Cohort A1 and A2) only: Previously received radiopharmaceutical or radioligand therapy. For participants with prostate cancer, prior ¹⁷⁷Lu-prostate-specific membrane antigen (PSMA) is permitted.\n* Has a history of ongoing acute pancreatitis within 1 year of screening.\n* Previously received any prior hemi-body or whole-body radiotherapy, or prior external beam radiation therapy (EBRT) to greater than 25% of the bone marrow.\n* A bone superscan, defined as a bone scan that demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint genitourinary tract activity.\n* Has evidence of ongoing and untreated urinary tract obstruction or unmanageable urinary incontinence.\n* Have known active hepatitis B virus (HBV). Exception: Individuals with chronic HBV if they:\n\n  * Have positive HBsAg\n  * Are on suppressive antiviral therapy, as allowed per local regulations prior to C1D1\n  * Remain on the same antiviral treatment throughout study, and should follow local standards for continuation of therapy after completion of trial therapy.\n  * Have undetectable HBV DNA ≤14 days of C1D1.\n* Have known active hepatitis C virus (HCV). Exception: Individuals previously treated for HCV if they:\n\n  * Completed curative antiviral therapy.\n  * Have an HCV viral load below the limit of quantification ≤14 days of C1D1 and.\n  * Are positive for anti-HCV antibodies and negative for HCV ribonucleic acid (RNA) before randomization.\n* Have untreated human immunodeficiency virus (HIV) infection. Exception: Individuals who have well-controlled HIV infection\u002Fdisease and they:\n\n  * Are on a stable and permitted antiretroviral therapy (ART) regimen without changes in drug or dose, for at least 4 weeks prior to C1D1\n  * Have a viral load of \\\u003C400 copies\u002FmL ≤14 days of C1D1.\n  * Have a CD4+ T-cell count ≥350 cells\u002FmL ≤14 days of C1D1.\n  * Have not had an opportunistic infection within the past 12 months.\n* Has an active second malignancy unless in remission with life expectancy greater than 2 years.\n* Has known hypersensitivity to any component or excipient of LY4257496.","ALL","18 Years",{"count":21,"type":22},421,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.",[28,29,30,31,32,33,34],"Breast Neoplasms","Colorectal Neoplasms","Prostate Neoplasm","Endometrial Neoplasms","Neoplasm Metastasis","Stomach Neoplasms","Esophageal Neoplasms",[36],"GRPR-positive","RECRUITING","2026-06-19",{"date":40,"type":41},"2026-06-23","ACTUAL",{"date":43,"type":41},"2025-08-06",{"date":45,"type":22},"2035-04",{"name":47,"class":48},"Eli Lilly and Company","INDUSTRY",32,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100609377","phase-1-a-study-of-ly4337713-in-participants-with-fap-positive-solid-tumors-100609377","NCT07213791","A Study of LY4337713 in Participants With FAP-Positive Solid Tumors","A Dose Escalation and Dose Optimization Phase 1a\u002F1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)","FiREBOLT","Inclusion Criteria:\n\n* Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment\n* Must have histologically or cytologically confirmed diagnosis of one of the following:\n\n  * Adenocarcinoma of the pancreas\n  * Hormone receptor (HR)-positive human epidermal growth factor 2 (HER2)-negative breast cancer\n  * HER2-positive breast cancer\n  * Triple negative breast cancer (TNBC)\n  * Platinum-resistant or refractory ovarian cancer (including ovarian carcinosarcoma)\n  * Other solid tumors\n\n    * Gastric cancer (adenocarcinoma)\n    * Colorectal cancer (CRC)\n    * Esophageal cancer (squamous cell carcinoma or adenocarcinoma)\n    * Cholangiocarcinoma\n* Must have received prior treatments as indicated below:\n\n  * Phase 1a\n\n    * Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease.\n    * HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4\u002F6 inhibitor.\n    * HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available).\n    * TNBC: Participants must have received at least 2 lines of therapy for metastatic disease.\n    * Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy.\n    * Other solid tumors (gastric cancer, CRC, esophageal and cholangiocarcinoma): Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; including prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor.\n  * Phase 1b:\n\n    * Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy.\n* Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.\n* Measured creatinine clearance ≥60 milliliters per minute (mL\u002Fmin)\n\nExclusion Criteria:\n\n* Have known active central nervous system (CNS) metastases or carcinomatous meningitis.\n* Have significant cardiovascular disease\n* Have prolongation of the corrected QTcF \\>470 milliseconds (msec) during screening. QTcF is calculated using Fridericia's Formula: QTcF = QT\u002F(RR0.33)\n* Have evidence of ongoing and untreated urinary tract obstruction\n* Had previous hemi- or total-body radiation.\n* Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell \\[CAR-T therapy, T-cell receptor \\[TCR\\] therapy, etc.)\n* Unable to lie flat during, or otherwise tolerate, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI).",{"count":59,"type":22},241,[25],"This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.",[63,28,64,29,34,33,65],"Ovarian Neoplasms","Pancreatic Intraductal Neoplasms","Cholangiocarcinoma",[67,68,69,70],"Cancer-associated fibroblasts (CAF)","Lutetium-177","LuFAP","Lu-177-FAP","2026-06-03",{"date":73,"type":41},"2026-06-04",{"date":75,"type":41},"2025-10-22",{"date":77,"type":22},"2033-03",{"name":47,"class":48},30,{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100552196","phase-1-substudy-06c-a-study-of-investigational-agents-with-pembrolizumab-mk-3475-and-chemotherapy-in-participants-with-first-line-locally-advanced-unresectablemetastatic-gastroesophageal-adenocarcinoma-mk-3475-06ckeymaker-u06-100552196","NCT06469944","Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable\u002FMetastatic Gastroesophageal Adenocarcinoma (MK-3475-06C\u002FKEYMAKER-U06)","A Phase 1\u002F2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable\u002FMetastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically and\u002For cytologically confirmed diagnosis of previously untreated locally advanced unresectable or metastatic first-line (1L) gastroesophageal adenocarcinoma\n* Is not expected to require tumor resection during the treatment course\n* Tumor tissue must be confirmed as negative for human epidermal growth factor receptor 2 (HER2) expression as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines\n* Core\u002Fexcisional biopsy of a tumor lesion not previously irradiated has been provided\n* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline\n* Participants with endocrine-related AEs who are adequately treated with hormone replacement therapy are eligible\n* Has adequate organ function\n* Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as determined by the local site investigator\u002Fradiology assessment and verified by blinded independent central review (BICR)\n* Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days prior to the first dose of study intervention\n* Has a life expectancy of at least 6 months\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation\u002Frandomization\n* Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has squamous cell or undifferentiated gastroesophageal cancer.\n* Has had previous therapy for locally advanced unresectable or metastatic gastric\u002Fgastroesophageal junction (GEJ)\u002Fesophageal adenocarcinoma\n* Has experienced weight loss \\>20% over 3 months before the first dose of study intervention\n* Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing\n* Has Grade ≥2 peripheral neuropathy\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within 6 months preceding study intervention\n* Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment\n* Has history of human immunodeficiency virus (HIV) infection with Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has received prior treatment with a trophoblast antigen 2 (TROP2)-targeted or anti-human epidermal growth factor receptor 3 (HER3) targeted agents\n* Has received prior treatment with a topoisomerase I inhibitor-based antibody-drug conjugate (ADC) and\u002For a topoisomerase I inhibitor-based chemotherapy\n* Has received prior systemic anticancer therapy within 4 weeks before the first dose of study intervention\n* Has received prior therapy with an anti-Programmed Cell Death Protein 1 (PD-1), anti-Programmed Cell Death-Ligand 1 (PD-L1), anti-Programmed Cell Death-Ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (TCR)\n* Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation related toxicities, requiring corticosteroids\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Has received a strong inducer\u002Finhibitor of CYP3A4 that cannot be discontinued\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration\n* Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has Severe hypersensitivity (≥Grade 3) to pembrolizumab, sacituzumab tirumotecan, patritumab deruxtecan, or other biologic therapy, chemotherapy (ie, oxaliplatin, fluorouracil, capecitabine), leucovorin, levoleucovorin, or any of their excipients\n* Has active autoimmune disease that has required systemic treatment in the past 2 years\n* Has history of (noninfectious) pneumonitis or interstitial lung disease (ILD) that required steroids or has current pneumonitis or ILD, or where suspected ILD or pneumonitis cannot be ruled out by imaging at screening\n* Has an active infection requiring systemic therapy\n* Has concurrent active hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] positive and\u002For detectable HBV DNA) and hepatitis C virus (defined as anti-hepatitis C virus \\[HCV\\] Ab positive and detectable HCV ribonucleic acid \\[RNA\\] infection or a known history of hepatitis B and\u002For C infection\n* Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's ability to cooperate with the requirements of the study\n* Has gastrointestinal (GI) obstruction, poor oral intake, or difficulty in taking oral medication\n* Has poorly controlled diarrhea\n* Has had a major surgery or significant traumatic injury within 4 weeks before the first dose of study intervention\n* Has history of allogeneic tissue\u002Fsolid organ transplant\n* Has not adequately recovered from major surgery or has ongoing surgical complications",{"count":88,"type":22},160,[25,90],"PHASE2","This is a phase 1\u002F2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment of participants with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric, gastroesophageal junction, or esophageal adenocarcinoma.\n\nThis substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to evaluate the safety and tolerability, and to establish a recommended Phase 2 dose (RP2D) for investigational agents in combination with chemotherapy and immunotherapy. There is no formal hypothesis in this study.",[93,94,34,95],"Gastroesophageal Junction","Gastroesophageal Adenocarcinoma","Esophageal Cancer",[97,98,99],"Programmed Cell Death-1 (PD1, PD-1)","Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)","Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)","2026-05-21",{"date":102,"type":41},"2026-05-26",{"date":104,"type":41},"2024-09-20",{"date":106,"type":22},"2029-09-12",{"name":108,"class":48},"Merck Sharp & Dohme LLC",51,{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":117,"targetDuration":119,"studyType":120,"phases":4,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":138},"100492964","rehabilitation-and-recovery-for-persons-with-esophageal-or-gastric-cancer-100492964","NCT05698992","Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer","Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer - a Clinical Trial Evaluating and Implementing a Model for Evidence-based Cancer Rehabilitation","Inclusion Criteria:\n\n* over 18 years of age\n* esophageal or gastric cancer\n* living in Southern Sweden (Skåne)\n* are planned to undergo curative surgerytreatment at Skåne University Hospital.\n\nExclusion Criteria:\n\n* unable to communicate in the Swedish language\n* suffering from a cognitive impairment that poses a barrier for participating in the study.",{"count":118,"type":22},100,"15 Months","OBSERVATIONAL","This study aims to develop and evaluate a model for systematic and evidence-based cancer rehabilitation for people with esophageal and gastric cancer to provide conditions for a better quality of life and fewer cancer-related symptoms.",[95,34,123,124],"Gastric Cancer","Stomach Neoplasm",[126,127],"Cancer rehabilitation","Recovery","2026-05-12",{"date":130,"type":41},"2026-05-15",{"date":132,"type":41},"2023-02-27",{"date":134,"type":22},"2027-12-31",{"name":136,"class":137},"Region Skane","OTHER",1,{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},"100550353","phase-1-substudy-06d-combination-therapies-in-second-line-2l-gastroesophageal-adenocarcinoma-mk-3475-06dkeymaker-u06-100550353","NCT06445972","Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D\u002FKeymaker-U06)","A Phase 1\u002F2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced\u002FMetastatic Gastroesophageal Adenocarcinoma: Substudy 06D","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically and\u002For cytologically confirmed diagnosis of previously treated, second line (2L) (received first line (1L) treatment) gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma\n* Has metastatic disease or locally advanced, unresectable disease\n* Has experienced documented objective radiographic or clinical disease progression during or after 1L therapy containing any platinum\u002Ffluoropyrimidine doublet with or without immunotherapy\n* Tumor tissue must be confirmed as negative for HER2 expression (IHC 0\u002F1+ or IHC2+\u002Fin situ hybridization negative) as classified by American Society of Clinical Oncology\u002FCollege of American Pathologists (ASCO-CAP) guidelines\n* Can provide a core\u002Fexcisional biopsy of a tumor lesion not previously irradiated (collected from a biopsy performed after the most recent systemic anticancer therapy regimen)\n* AEs due to previous anticancer therapies must be ≤Grade 1 or baseline (except alopecia and vitiligo). Endocrine-related AEs adequately treated with hormone replacement are acceptable\n* Has Eastern Cooperative Oncology Group performance status of 0 or 1\n* Has a life expectancy of at least 3 months\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation\u002Frandomization\n* Participants with history of Hepatitis C Virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Human Immunodeficiency Virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has squamous cell or undifferentiated gastroesophageal cancer\n* Has experienced weight loss \\>20% over 3 months before the first dose of study intervention\n* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing\n* Has Grade ≥2 peripheral neuropathy\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Has a serious or nonhealing wound or peptic ulcer or bone fracture within 28 days prior to allocation\u002Frandomization\n* Has a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (hemicolectomy or extensive small intestine resection with chronic diarrhea)\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease\n* Has experienced any arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to allocation\u002Frandomization\n* Has uncontrolled arterial hypertension ≥150\u002F≥90 mm mercury (Hg)\n* Has accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 2 weeks prior to enrollment\n* Has undergone major surgery within 28 days prior to allocation\u002Frandomization, or central venous access device placement within 7 days prior to allocation\u002Frandomization or planned major surgery following initiation of study treatment\n* Is receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin or similar agents\n* Is receiving chronic therapy with nonsteroidal anti-inflammatory agents or other antiplatelet agents\n* Has a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism during the 3 months prior to allocation\u002Frandomization\n* Has significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to study entry\n* Has history of GI perforation and\u002For fistulae within 6 months prior to allocation\u002Frandomization\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)- or HER3-targeted agent, topoisomerase 1 inhibitor-based ADC and\u002For a topoisomerase 1 inhibitor-based chemotherapy, or any previous systemic therapy targeting vascular endothelial growth factor (VEGF) or the vascular endothelial growth factor receptor (VEGFR) signaling pathways\n* Has received prior systemic anticancer therapy within 4 weeks before the first dose of study intervention\n* Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded\n* Has known active central nervous system metastases and\u002For carcinomatous meningitis\n* Has an active infection requiring systemic therapy\n* Has concurrent active Hepatitis B (defined as HBsAg positive and\u002For detectable HBV deoxyribonucleic acid) and Hepatitis C virus (defined as anti-HCV antibody positive and detectable HCV ribonucleic acid) infection\n* History of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease, or where suspected ILD or pneumonitis cannot be ruled out by imaging at screening\n* Has severe hypersensitivity (Grade ≥3) to MK-2870, or HER3-DXd, any of their excipients, and\u002For to another biologic therapy\n* Has not adequately recovered from major surgery or have ongoing surgical complications",{"count":147,"type":22},210,[25,90],"This is a phase 1\u002F2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or metastatic gastric adenocarcinoma, gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who have failed 1 prior line of therapy. This is an estimation study, and no formal hypothesis testing will be performed.",[93,94,34,95],[152,98,99],"Programmed Cell Death 1 (PD1, PD-1)","2026-05-08",{"date":128,"type":41},{"date":156,"type":41},"2024-08-07",{"date":158,"type":22},"2030-08-08",{"name":108,"class":48},45,{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":170,"briefSummary":171,"conditions":172,"keywords":181,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":193},"100545354","phase-1-a-phase-iii-trial-of-ucb4594-in-participants-with-advanced-cancer-100545354","NCT06380816","A Phase I\u002FII Trial of UCB4594 in Participants With Advanced Cancer","A Cancer Research UK Phase I\u002FII Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of UCB4594 Alone and in Combination With Anti-cancer Treatments in Participants With Advanced Malignancies","Inclusion Criteria:\n\n1. Written (signed and dated) informed consent and capable of co-operating with investigational medicinal product (IMP) administration and follow-up\n2. Participant population: Histologically or cytologically proven advanced solid tumours (as specified below), refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator or is declined by the participant. Module A (dose escalation): Tumour types which have shown high levels of human HLA-G expression (as reported in the literature): head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, triple-negative breast cancer, renal cell cancer (clear cell only), oesophago-gastric cancer (excluding gastrointestinal stromal tumour), cervical cancer, ovarian cancer, pancreatic cancer. N.B. Participants with small cell type cancers on histology\u002Fcytology are excluded. Pre-treatment biopsies are mandatory for all participants. Paired biopsies will be mandatory for participants from doses of 30 mg and higher. Participants must have disease amenable to biopsy (excluding bone metastases) as deemed safe by the Investigator\n3. Measurable disease, according to RECIST v1.1\n4. Life expectancy of at least 12 weeks\n5. Eastern Cooperative Oncology Group performance status of 0 or 1\n6. Haematological and biochemical indices within defined ranges. These measurements should be performed to confirm the patient's eligibility to participate in the trial\n7. Aged 18 years or over at the time consent is given. Participants aged 16-17 years may be eligible for recruitment to the backfill cohorts in dose escalation once adequate safety and toxicity data have been established in participants aged 18 years or over. All relevant data will be reviewed and a decision on the inclusion of participants aged 16-17 years will be made by the Trial Management Group\n\nExclusion Criteria:\n\n1. Radiotherapy (except palliative), endocrine therapy (unless for non-malignant disease), chemotherapy, targeted therapy or immunotherapy, or any other IMPs during the previous 4 weeks or 5 half-lives (whichever is shorter) before the first dose of IMP\n2. Ongoing toxicity of previous treatments \\>CTCAE Grade 1 (except alopecia of any grade, stable Grade 2 peripheral neuropathy or hormone-replacement therapy (HRT)-managed endocrine disorders)\n3. Patients with rapidly progressing \u002F symptomatically deteriorating brain\u002Fleptomeningeal metastases\u002Funtreated brain metastases are excluded. Patients with previously treated brain metastases are eligible if they haven't had a seizure or a clinically significant change in neurological status or required steroids in the last 2 weeks\n4. Pregnant or breastfeeding female patients (or planning to breastfeed)\n5. Women of childbearing potential. However, those not already pregnant or breastfeeding (or who discontinue breastfeeding) and meet the following are eligible:\n\n   5.1. Have a negative serum pregnancy test within 7 days before enrolment and either:\n\n   5.2.1. Agree to a form of highly effective contraception plus a barrier method, or\n\n   5.2.2. Agree to sexual abstinence\n\n   Effective from the negative pregnancy test, throughout the trial and for 10 months after the last dose of UCB4594\n6. Male patients with partners of childbearing potential. However, patients who meet the following are eligible:\n\n   6.1. Agree to a barrier method of contraception or sexual abstinence\n\n   6.2. Males with pregnant or breastfeeding partners must use barrier method contraception to prevent exposure of the foetus or neonate\n\n   6.3. Non-vasectomised males must also ensure any partner of childbearing potential uses highly effective contraception or agrees to sexual abstinence\n\n   Effective from the date of the first dose of UCB4594, throughout the trial and for 5 months after the last dose of UCB4594 N.B. Males must refrain from donating sperm for the same period\n7. Surgery from which the patient has not yet recovered\n8. High medical risk because of non-malignant systemic disease, including serious or uncontrolled infection (requiring intravenous antibiotics) or unexplained fever \\>38°C within 2 weeks prior to the first dose of UCB4594\n9. Known to be serologically positive for hepatitis B virus, hepatitis C virus or human immunodeficiency virus\n10. Active or suspected autoimmune disease, or any history of autoimmune condition that required systemic corticosteroids or immunosuppressive agents. Patients who have ever had a transplant are excluded. This does not apply to patients with: vitiligo, alopecia, or type I diabetes mellitus, psoriasis not requiring chronic systemic immunosuppressive treatment within the past 2 years, stable autoimmune-mediated hypothyroidism on HRT, and Raynaud's syndrome\n11. Are being treated with escalating or supraphysiologic doses of corticosteroids or immunosuppressive agents. Participants with immunotherapy-related hypophysitis adequately treated with physiologic doses of steroids are not excluded. Use of topical, ophthalmic, inhaled, intermittent steroid injections, and intranasal corticosteroids are permitted\n12. Hypersensitivity to the ingredients\u002Fexcipients (including polysorbate 80) in UCB4594\n13. History of significant toxicities from treatment of immune checkpoint inhibitors (CPIs) that necessitated permanent discontinuation (Patients who started on combination CPI \\[e.g., ipilimumab\u002Fnivolumab\\] and had toxicity requiring discontinuation of one CPI \\[e.g., continued with nivolumab single agent\\] are not excluded)\n14. History of Grade ≥3 infusion-related reaction to monoclonal antibodies or similar drugs\n15. Prior treatment with HLA-G, immunoglobulin-like transcript (ILT)2 or ILT4-targeting drug\n16. Live, attenuated vaccine within 28 days prior to the first dose of IMP\n17. Increased risk due to tumour flare (e.g., an initial increase in tumour size that may lead to obstruction of airways, etc)\n18. Significant active pulmonary disease or condition at screening, including:\n\n    18.1. Lymphangitis carcinomatosa\n\n    18.2. History of interstitial lung disease or pulmonary fibrosis\n\n    18.3. History of pulmonary inflammatory disease\n19. Evidence of bleeding diathesis\n20. Significant cardiovascular disease, defined as a history of: congestive heart failure requiring therapy or left ventricular ejection fraction \\\u003C40%, unstable angina pectoris or myocardial infarction within 6 months prior to entry, or current poorly controlled angina (symptoms weekly or more), clinically significant cardiac arrhythmia within 6 months prior to entry (asymptomatic atrial fibrillation or asymptomatic first-degree heart block permitted), or myocarditis. Presence of symptomatic or severe valvular heart disease. Baseline QT interval corrected by Fridericia \\>450 msec for males and \\>470 msec for females on triplicate electrocardiogram is ineligible\n21. Participant in or plans to join another interventional trial\n22. Other current malignancies. Cancer survivors who have undergone potentially curative therapy for prior malignancy with no evidence of disease for 3+ years are eligible\n23. Any other condition that, in the Investigator's opinion, means the trial is not in the patient's best interest",{"count":169,"type":22},167,[25,90],"This clinical trial is looking at UCB4594. This is the first time the drug is being tested in humans. UCB4594 is a type of drug called a monoclonal antibody. It has been designed to work by targeting a protein called human leucocyte antigen G (HLA-G) that is found in high levels on some cancer cells. By attaching itself to this protein it may help the immune system to attack and kill the cancer cells.\n\nThe four main aims of the clinical trial are to find out:\n\n1. The best dose of UCB4594 that can be given safely to participants in the trial.\n2. What the side effects of UCB4594 are and how they can be managed.\n3. What happens to UCB4594 inside the body and how it affects cancer cells.\n4. Whether UCB4594 can cause cancer to shrink.",[173,174,175,29,176,177,34,178,179,63,180],"Advanced Solid Tumours","Squamous Cell Carcinoma of Head and Neck","Carcinoma, Non-Small-Cell Lung","Triple Negative Breast Neoplasms","Carcinoma, Renal Cell (Clear Cell Only)","Stomach Neoplasms (Excluding Gastrointestinal Stromal Tumors)","Uterine Cervical Neoplasms","Pancreatic Neoplasms",[182,183,184],"HLA-G","Monoclonal Antibody","Cancer","2026-05-05",{"date":153,"type":41},{"date":188,"type":41},"2024-07-09",{"date":190,"type":22},"2029-11",{"name":192,"class":137},"Cancer Research UK",4,{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":138},"100632822","a-clinical-study-on-the-effect-of-massaging-tian-tu-acupoint-on-coughing-after-esophageal-surgery-100632822","NCT07518680","A Clinical Study on the Effect of Massaging Tian Tu Acupoint on Coughing After Esophageal Surgery","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form and follow the requirements of the protocol;\n2. Age 18 to 75 years old (inclusive), gender not limited;\n3. Patients who have undergone esophageal surgery (without intubation);\n4. Not taking psychotropic drugs, mentally sound, and likely to cooperate in completing the assessment and intervention.\n\nExclusion Criteria:\n\n1. The subjects or their family members request to withdraw from the study;\n2. Pregnancy or lactation period;\n3. Severe heart and lung diseases (such as heart failure, acute exacerbation of COPD, asthma, etc.);\n4. Skin damage or infection in the area of the Tiantu acupoint;\n5. Within the last month, have received other cough-related interventions (such as acupuncture, physical therapy);\n6. Other situations that the researcher deems unsuitable for participating in this clinical trial","75 Years",{"count":79,"type":22},[203],"NA","This study is a single-center, self-controlled trial. Patients will successively undergo voluntary coughing without intervention, a washout period, coughing stimulated by pressing the Tiantu acupoint, a washout period, and voluntary coughing without intervention. Vital signs of the patients before and after each cough will be recorded, as well as the changes in peak cough flow rate and intra-abdominal pressure after each cough. For peak cough flow rate and intra-abdominal pressure, three sets of data will be collected each time, and the best value will be taken. This pilot trial is conducted to verify the feasibility of the research design and to provide sample size estimation and data support for the main study.",[34],"NOT_YET_RECRUITING","2026-04-01",{"date":209,"type":41},"2026-04-08",{"date":211,"type":22},"2026-04-10",{"date":213,"type":22},"2026-05-31",{"name":215,"class":137},"Shanghai Zhongshan Hospital",{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":138},"100249843","mayo-clinic-upper-digestive-disease-survey-100249843","NCT02530983","Mayo Clinic Upper Digestive Disease Survey","UDD","Inclusion Criteria:\n\n* Patients undergoing or having already undergone an esophagectomy or esophageal reconstruction.",{"count":224,"type":22},1000,"The Mayo Clinic Conduit Report Card Questionnaires have been created in order to have a consistent evaluation tools for patients undergoing esophageal reconstruction or treatment or patients that are experiencing an upper digestive disease in order to standardize and validate outcome measures. Data will be used to establish the validation of the questionnaires\u002Fsurvey. Data will also lead to the establishment of \"normal\" or expected scores for patients undergoing each type of esophagectomy procedure and for upper digestive diseases. Data will contribute to creating treatment algorithms for symptom management for upper digestive diseases and for post-operative complications and symptoms as well as contribute to pre-operative education.",[34,227,228,95,229,230,231,232,233],"Cancer of Esophagus","Cancer of the Esophagus","Esophagus Cancer","Neoplasm, Esophageal","Esophagectomy","Abnormalities, Digestive System","Digestive System Abnormalities","2026-03-24",{"date":236,"type":41},"2026-03-30",{"date":238,"type":41},"2015-08-15",{"date":240,"type":22},"2028-12",{"name":242,"class":137},"Mayo Clinic",{"id":244,"slug":245,"hasResults":12,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":138},"100630045","proximal-versus-total-gastrectomy-for-locally-advanced-siewert-type-ii-iii-gastroesophageal-junction-cancer-100630045","NCT07482566","Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer","A Multicenter Prospective Randomized Double-Blind Clinical Trial Comparing Proximal Gastrectomy and Total Gastrectomy in Patients With Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer","SIEWERT-RCT","Inclusion Criteria:\n\n* Age between 18 and 90 years\n* Histologically confirmed locally advanced Siewert type II-III gastroesophageal junction cancer\n* Considered operable after multidisciplinary tumor board evaluation\n* Candidate for curative surgical resection with D2 lymphadenectomy\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Early-stage gastroesophageal junction cancer\n* Gastric cancers located in the antrum or corpus\n* Severe anesthetic risk (American Society of Anesthesiologists \\[ASA\\] class IV or higher)\n* Pregnancy\n* Patients unwilling or unable to provide informed consent","90 Years",{"count":253,"type":22},120,[203],"This multicenter prospective randomized clinical trial aims to compare the safety and oncological effectiveness of proximal gastrectomy and total gastrectomy in patients with locally advanced Siewert type II-III gastroesophageal junction cancer. Eligible patients will be randomly assigned to undergo either proximal gastrectomy or total gastrectomy using open, laparoscopic, or robotic surgical approaches according to clinical suitability. The primary outcome of the study is 3-year disease-free survival. Secondary outcomes include postoperative mortality, postoperative complications, and the number of metastatic lymph nodes retrieved. Patients will be followed for up to five years after surgery to evaluate long-term oncological outcomes.",[257,33,34],"Gastroesophageal Junction Cancer",[259,260,261,262,263],"Siewert Type II","Siewert Type III","Proximal Gastrectomy","Total Gastrectomy","Gastric Cancer Surgery","2026-03-18",{"date":266,"type":41},"2026-03-20",{"date":268,"type":41},"2026-02-01",{"date":270,"type":22},"2033-02-01",{"name":272,"class":273},"Nurettin Şahin","OTHER_GOV",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":18,"minAge":281,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100506552","effects-of-bright-light-exposure-combined-with-specific-exercise-training-best-program-in-patients-with-cancer-100506552","NCT05875870","Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With Cancer","Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program on Sleep-Wake Rhythm, Physical and Psychological Symptoms, and Quality of Life of Patients With Thoracic Cancer: A Series Study.","Inclusion Criteria:\n\n1. Patients with newly diagnosed primary lung cancer or esophageal cancer, from the first stage to the third stage.\n2. At least 20 years of age.\n3. Able to communicate in Mandarin Chinese or Taiwanese.\n4. Literate and free from cognitive disabilities.\n5. The attending physician agrees to participate in the study.\n6. Those who can connect to the Internet with mobile devices such as computers, mobile phones, and tablets, or those whose family members can assist in the operation.\n7. Those with Karnofsky Performance Scale (KPS) greater than or equal to 70 points.\n8. Those who are hospitalized for lung cancer or esophageal cancer lesion resection.\n\nExclusion Criteria:\n\n1. Congestive heart failure.\n2. Orthopedic diseases of the lower extremities that limit one's walking ability.","20 Years",{"count":283,"type":22},200,[203],"This study plans to investigate the effectiveness of six-week light exposure combined with an exercise training program on improving sleep-wake rhythm, physical and mental symptoms, quality of life, one-year recurrence rate, and one-year survival rate of patients with lung and esophageal cancer.",[287,34],"Lung Neoplasm","2026-02-13",{"date":290,"type":41},"2026-02-17",{"date":292,"type":41},"2023-07-24",{"date":294,"type":22},"2028-05-15",{"name":296,"class":273},"Taipei Veterans General Hospital, Taiwan",2,{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":138},"100613883","omega-3-fatty-acids-with-pd-1-inhibitors-in-advanced-esophageal-cancer-100613883","NCT07272382","Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer","Effect of Omega-3 Fatty Acids on PD-1 Inhibitor Therapy in Advanced Esophageal Cancer (ESO-Shanghai28): A Phase II Randomized Controlled Trial","ESO-Shanghai28","Inclusion Criteria： Age ≥18 years; ECOG 0-2. Histologically confirmed recurrent\u002Fmetastatic esophageal cancer (AJCC 8th; de novo stage IV or relapse after prior therapy).\n\nPD-1 inhibitor naïve, or prior PD-1 stopped \\>3 months with subsequent progression (not primary PD-1 resistance).\n\nAdequate organ function per protocol (hematologic, hepatic, renal). Women of childbearing potential: negative pregnancy test and agree to effective contraception.\n\nSigned informed consent.\n\nExclusion Criteria： PD-1 inhibitor resistance or refractory disease to prior PD-1. Esophageal fistula present or strongly suspected. Active autoimmune disease or immunodeficiency requiring systemic therapy (protocol-defined exceptions allowed, e.g., treated hypothyroidism; controlled type 1 diabetes).\n\nSystemic corticosteroids or other immunosuppressants requiring ongoing use (physiologic or topical steroids allowed).\n\nInterstitial lung disease\u002Fpneumonitis history or active pneumonitis on screening CT.\n\nUncontrolled cardiovascular disease (e.g., NYHA ≥ II heart failure, unstable angina, recent MI, significant uncontrolled arrhythmias).\n\nSerious active infection, including active TB; uncontrolled viral hepatitis (active HBV\u002FHCV per protocol).\n\nPregnant or breastfeeding. Recent major surgery (per protocol window) or high bleeding risk\u002Ftherapeutic anticoagulation not suitable for omega-3 use.\n\nOther conditions that, in investigator's judgment, preclude protocol compliance or safety.",{"count":307,"type":22},142,[203],"This is a randomized, double-blind, placebo-controlled phase II clinical trial designed to evaluate whether adding omega-3 fatty acids improves outcomes in adult patients with recurrent or metastatic esophageal cancer receiving PD-1 inhibitor therapy.\n\nThe main questions are:\n\nCompared with placebo, does omega-3 (EPA+DHA) increase the longitudinal change in skeletal muscle index (ΔSMI) over 6 months? Does it improve clinical outcomes and favorably modulate immune and metabolic biomarkers as well as patient-reported outcomes ?\n\nParticipants will be randomized 1:1 to:\n\nIntervention: Standard PD-1 therapy plus oral omega-3 (EPA 2.5 g + DHA 1.25 g per day) for 6 months.\n\nControl: Standard PD-1 therapy plus matching placebo for 6 months. Participants will attend study visits at baseline, 3 months, and 6 months (then every 3 months up to 2 years), undergo body composition and functional assessments, blood sampling, and questionnaires, and have treatment adherence assessed per protocol. Pre-specified exploratory biomarker analyses will be conducted to support mechanism research.",[34],"2025-12-08",{"date":313,"type":41},"2025-12-09",{"date":315,"type":41},"2025-06-05",{"date":317,"type":22},"2027-06-05",{"name":319,"class":137},"Fudan University",{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":327,"enrollmentInfo":328,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":330,"conditions":331,"keywords":337,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":138},"100422394","endoscopic-resection-of-gastrointestinal-neoplasms-100422394","NCT04780256","Endoscopic Resection of Gastrointestinal Neoplasms","Retrospective Study of Efficacy and Safety of the Endoscopic Removal of Cancerous and Precancerous Lesions of the Upper and Lower Digestive Tract","Inclusion Criteria:\n\n* 18 years or older\n* all patients who have undergone endoscopic resection of an upper or lower digestive tract tumor\n\nExclusion Criteria:\n\n* age under 18\n* inability to provide informed consent","100 Years",{"count":329,"type":22},2000,"The study aims to retrospectively investigate the endoscopic resection procedures of cancerous and precancerous lesions of the upper and lower digestive tract in order to evaluate the efficacy and safety outcomes and to compare different resection techniques. In particular, the resection techniques investigated will be mucosectomy, en bloc and piecemeal, endoscopic submucosal dissection (ESD) and its variants, full-thickness resection. The anatomical districts involved will be the esophagus, stomach, duodenum, colon and rectum.",[332,333,334,335,34,336],"Endoscopic Mucosal Resection","Endoscopic Submucosal Dissection","Gastric Neoplasm","Colonic Neoplasms","Duodenal Neoplasms",[338,339,340,341,342],"Endoscopic mucosal resection (EMR)","Endoscopic submucosal dissection (ESD)","Endoscopic full thickness resection (EFTR)","Colorectal ESD","Colorectal EMR","2025-09-30",{"date":345,"type":41},"2025-10-03",{"date":347,"type":41},"2021-03-15",{"date":349,"type":22},"2025-12",{"name":351,"class":273},"Azienda USL Reggio Emilia - IRCCS",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":358,"sex":18,"minAge":359,"maxAge":4,"enrollmentInfo":360,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":138},"100595679","diagnosis-of-multiple-cancer-and-monitoring-of-minimal-residual-tumors-after-treatment-using-blood-and-high-sensitivity-genetic-analysis-techniques-100595679","NCT07035587","Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques","Inclusion Criteria:\n\n* Age ≥ 19 years\n* Voluntarily agreed to participate and provided informed consent\n* Able to donate blood without health risks\n* Underwent or is scheduled to undergo surgery or chemotherapy for therapeutic purposes for cancer (for cancer group)\n* Diagnosed with one of the following cancers: ovarian, lung, pancreatic, colorectal, esophageal, breast, bladder, kidney, or gastric cancer\n* Control group: asymptomatic individuals with gallstones or benign polyps, or subjects undergoing routine health screenings\n* Control group must have confirmed benign findings through imaging (ultrasound, CT, LDCT, colonoscopy)\n\nExclusion Criteria:\n\n* Age \\\u003C 19 years\n* Patients with mental retardation or severe psychiatric disorders affecting informed consent\n* History of HIV, HTLV, or syphilis infection\n* History of other malignancy within 5 years (for cancer group)\n* No somatic mutation detected in tumor or pre-treatment cfDNA (for cancer group)\n* Control group with any past or current cancer diagnosis\n* Control group with high-grade adenoma, symptomatic gallstones\u002Fpolyps, or recent (\\\u003C6 months) abdominal surgery\n* Pregnant or breastfeeding women\n* Any other reason deemed inappropriate by the investigator",true,"19 Years",{"count":361,"type":22},1200,"This is a combined prospective and retrospective observational study aiming to validate a highly sensitive and specific blood-based method for the early diagnosis and post-treatment monitoring of multiple cancers. The study leverages a newly developed sequencing method to improve the detection of circulating tumor DNA (ctDNA) in blood, focusing on enhancing sensitivity and specificity in clinical applications.\n\nThe study targets patients with ovarian, lung, pancreatic, colorectal, esophageal, breast, kidney, bladder, and gastric cancer, as well as healthy controls with asymptomatic gallstones, benign polyps, or individuals undergoing routine medical screening. Blood samples will be analyzed for cell-free DNA (cfDNA), RNA, and protein profiles. A key objective is to determine how much the newly developed method increases the sensitivity and specificity of ctDNA detection, especially in early-stage cancers and minimal residual disease (MRD) after treatment.\n\nThe method evaluates the variant allele frequency (VAF) of ctDNA to detect residual disease and track tumor dynamics. Serial blood sampling will be conducted before and after surgery or chemotherapy and during follow-up outpatient visits in cancer patients, while one-time sampling will be done for controls. Additionally, tissue biopsies collected during surgery will be used to analyze concordance between tumor-specific mutations and those found in ctDNA.\n\nPrimary outcome measures include quantitative differences in ctDNA or RNA levels between cancer and control groups. Secondary outcomes assess the clinical correlation between changes in ctDNA VAF and patient outcomes such as recurrence and survival. Statistical tools including ROC curve analysis, Cox regression, and log-rank tests will be used to quantify performance.\n\nThis study seeks to establish a clinically robust, non-invasive diagnostic tool that enables earlier detection and more precise treatment decisions, while potentially reducing physical, psychological, and socioeconomic burdens related to cancer care.",[364,180,29,34,63,33,365,366],"Lung Neoplasms","Neoplasm Micrometastasis","Neoplasms","2025-06-15",{"date":369,"type":41},"2025-06-25",{"date":371,"type":41},"2024-08-21",{"date":373,"type":22},"2029-07-28",{"name":375,"class":137},"Yonsei University",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":386,"conditions":387,"keywords":395,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":408},"100511807","phase-1-htl0039732-in-participants-with-advanced-solid-tumours-100511807","NCT05944237","HTL0039732 in Participants With Advanced Solid Tumours","A Cancer Research UK Phase I\u002FIIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours","Inclusion Criteria:\n\n1. Written (signed and dated) informed consent and capable of co-operating with investigational medicinal product administration and follow-up.\n2. Phase 1, dose escalation phase\n\n   Part A (HTL0039732 monotherapy):\n   * Histologically or cytologically proven advanced solid tumour, refractory to conventional treatment, or for which no further conventional therapy is considered appropriate by the Investigator or is declined by the potential participant.\n   * At least 1 measurable lesion according to RECIST v1.1, which (in the Investigator's opinion) has had objective radiological progression on or after the last therapy, or at least one assessable lesion e.g. pleural or peritoneal thickening that does not fulfil RECIST v1.1 criteria for measurable disease.\n\n     a. Consent for fresh tumour biopsy sample(s) at time of PD, if the participant has accessible disease and is eligible to receive atezolizumab. Optional at time of disease progression.\n   * Consent to access and analysis of any available archival tissue or a fresh tumour sample at baseline, if archival tissue is unavailable.\n   * Consent for fresh tumour biopsy sample(s) at time of PD, if the participant has accessible disease and is eligible to receive atezolizumab. Optional at time of disease progression.\n\n   Phase 1 Part B:\n\n   \\- Histologically proven advanced solid tumour where PGE2\u002FEP4 signalling is believed to be more prevalent or significant (such as microsatellite stable colorectal cancer (MSS CRC), gastro-esophageal cancer, head and neck squamous cell carcinoma (HNSCC), mCRPC, pancreatic cancer, lung cancer, bladder cancer, mesothelioma, cervical cancer, renal cancer, sarcoma, pheochromocytoma and cancers with PI3K\u002FAKT\u002FmTOR pathway activating mutations using a clinically-validated assay).\n\n   Phase 2a:\n\n   \\- Histologically proven advanced solid tumour, in line with indications listed below, refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator or is declined by the potential participant:\n   1. MSS CRC with PIK3CA or HER2 mutation, and\u002For other driver mutation as agreed with the Sponsor (genomic alteration to have been previously identified using a validated next-generation sequencing method performed on either tumour tissue or circulating tumour DNA \\[ctDNA\\]);\n   2. Gastric or gastroesophageal junction (GOJ) adenocarcinoma;\n   3. Clear cell renal cell carcinoma;\n   4. mCRPC\n\n   Phase 1 Part B and Phase 2a:\n   * Consent to access and analysis of any available archival tissue.\n   * Consent for fresh tumour biopsy samples at baseline and on treatment. However, the following exceptions will be permitted if archival tissue is available at the recruiting site:\n\n     1. Patients with mCRPC: biopsies are not required for those whose only safely accessible lesions are bone metastases that lack an accessible soft tissue component.\n     2. For the first 12 participants in each indication: the on-trial biopsy is optional; and the baseline biopsy is mandatory if there is a safely accessible lesion but may be omitted for patients who have no safely accessible lesion, to permit their inclusion in the study. This will continually be assessed through the study.\n   * Disease refractory to conventional treatment, or for which no further conventional therapy is considered appropriate by the Investigator or is declined by the participant.\n   * Except for mCRPC, at least 1 measurable lesion according to RECIST v1.1, which (in the Investigator's opinion) has had objective radiological progression on or after the last therapy. Potential participants with mCRPC may instead have had PD according to PCWG3 criteria.\n\n     1. Previously irradiated lesions cannot be counted as target lesions unless clearly progressed after the radiotherapy.\n     2. Lesions that are intended to be biopsied should not be counted as target lesions (those undergoing biopsy must have at least one target lesion that is not intended to be biopsied).\n   * For indications where anti-PD-1\u002FPD-L1 therapy is standard of care (such as clear cell renal cell carcinoma, or gastric or GOJ adenocarcinoma with elevated PD-L1 expression), patients must have received that therapy and must be considered to have had progressive disease by the Investigator either on, or within 6 months after, that treatment.\n3. Life expectancy of at least 12 weeks.\n4. Eastern Cooperative Oncology Group performance status of 0 or 1.\n5. Haematological and biochemical indices within the protocol specified ranges.\n6. Stable thyroid function tests. Stable doses of thyroxine replacement are permitted.\n7. Aged 18 years or over at the time consent is given.\n\nExclusion Criteria:\n\n1. Radiotherapy (except for palliative reasons), chemotherapy, non chemotherapy systemic anti-cancer therapy (apart from life-long hormone suppression such as luteinising hormone-releasing agents in participants with mCRPC) or investigational medicinal products during the 4 weeks prior to enrolment; or first dose of an immunotherapy during the previous 12 weeks before first dose of HTL0039732.\n2. Ongoing toxic manifestations of previous treatments that are Grade \\>1 per CTCAE v5.0.\n3. Any central nervous system metastases (unless potential participants have had local therapy and are asymptomatic, radiologically stable and have been off steroids for ≥4 weeks prior to enrolment).\n4. Women of child-bearing potential (or who are already pregnant or lactating). Exceptions apply.\n5. Men with partners of childbearing potential. Exceptions apply.\n6. Major thoracic or abdominal surgery from which the potential participant has not yet recovered.\n7. At high medical risk because of non-malignant systemic disease, including active uncontrolled infection.\n8. Known history of current or latent tuberculosis, HIV or Hepatitis B or C infection.\n9. Prior treatment with EP4 inhibitor.\n10. Treatment with selective cyclooxygenase-2 inhibitor in the 8 weeks prior to enrolment.\n11. Known hypersensitivity or intolerance to hydroxypropyl methylcellulose.\n12. Use of systemic immunosuppressive agent in the 2 weeks prior to enrolment. Exceptions apply.\n13. Significant cardiovascular disease.\n14. Known active peptic ulcer disease, or symptoms of gastritis, dyspepsia or gastro-esophageal reflux disease (one or more episodes per week).\n15. Current or planned participation in another interventional clinical trial, whilst taking part in this trial of HTL0039732.\n16. Limited ability to swallow or absorb oral medications.\n17. Any other condition that, in the Investigator's opinion, would mean that the trial is not in the best interests of the potential participant.\n\n    Phase 1 Part B and Phase 2a:\n18. Any live vaccines in the 4 weeks prior to enrolment.\n19. Diagnosis of immunodeficiency.\n20. Active autoimmune disease requiring systemic treatment in the 2 years prior to enrolment.\n21. History or clinical suspicion of interstitial lung disease, history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.\n22. Hypersensitivity to atezolizumab or any of its excipients.\n23. Prior adverse reaction to cancer immunotherapy that required steroid or other immunosuppressive treatment or led to discontinuation of that treatment.",{"count":384,"type":22},150,[25,90],"The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with advanced solid tumours.",[366,388,33,34,389,29,180,364,390,391,179,392,393,394],"Prostatic Neoplasms, Castration-Resistant","Head and Neck Neoplasms","Urinary Bladder Neoplasms","Mesothelioma, Malignant","Kidney Neoplasms","Sarcoma","Pheochromocytomas",[396,397,398,399,400],"EP4 antagonist","Anti-PD-1\u002FPD-L1 agents","PGE2","EP4","COX inhibitor",{"date":402,"type":41},"2025-06-08",{"date":404,"type":41},"2023-07-13",{"date":406,"type":22},"2027-06",{"name":192,"class":137},5,{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":4,"eligibilityCriteria":415,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":416,"targetDuration":4,"studyType":23,"phases":418,"briefSummary":419,"conditions":420,"keywords":422,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":138},"100521498","comparative-study-between-fc-sems-and-pc-sems-in-the-palliation-of-dysphagia-due-to-malignant-neoplasm-of-esophagus-100521498","NCT06070376","Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.","Comparative Study Between Fully Covered Esophageal Prosthesis (FC-SEMS) and Partially Covered Esophageal Prosthesis (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.","Inclusion Criteria:\n\n* Patients with advanced malignant neoplasm of the esophagus, whether or not undergoing chemotherapy or radiotherapy;\n* Dysphagia score greater than 2 or presence of malignant esophagorespiratory fistula;\n* Indication of palliation of dysphagia through the placement of esophageal prostheses in a multidisciplinary meeting.\n\nExclusion Criteria:\n\n* Patients under 18 years;\n* Extraesophageal neoplasms;\n* Lesions with longitudinal extension less than 30 mm;\n* Previous treatment with esophageal prosthesis;\n* Tumors easily transposed to standard endoscope (9.8mm).",{"count":417,"type":22},34,[203],"Esophageal cancer is the seventh most common type of cancer in the world, with an estimated global incidence of 604,100 new cases per year. The main symptom of esophageal cancer is dysphagia, associated or not with weight loss. Unfortunately, due to asymptomatic presentation in the early stages, more than half of patients are diagnosed in advanced stages of the disease, becoming ineligible for treatment with curative intent. In this sense, chemotherapy and radiotherapy are the pillars of palliative treatment, often regressing the injury and improving symptoms. However, some patients persist with dysphagia. In this scenario, esophageal prostheses are one of the main tools in the palliative treatment of esophageal cancer dysphagia, obtaining rapid and lasting relief of dysphagia. This study aims to compare fully covered (FC-SEMS) and partially covered (PC-SEMS) esophageal prostheses in this context, evaluating the number of reinterventions in each group, as well as the occurrence of adverse events. However, it is expected that with the data obtained it is possible to develop clearer and more effective protocols in the palliation of malignant dysphagia of esophageal stenosis.",[34,421],"Dysphagia",[34,423,424],"Palliation of dysphagia","Esophageal stent","2025-04-29",{"date":427,"type":41},"2025-05-01",{"date":429,"type":41},"2023-06-26",{"date":431,"type":22},"2026-08-26",{"name":433,"class":137},"Instituto do Cancer do Estado de São Paulo",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":443,"conditions":444,"keywords":446,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":447,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":138},"100522083","comparison-of-04-hyaluronic-acid-solution-versus-hydroxyethylamide-solution-in-submucosal-endoscopic-resections-100522083","NCT06077981","Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections","Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections of Superficial Malignant Esophageal Neoplasms: a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Superficial esophageal adenocarcinoma or squamous cell carcinoma with indication of ESD after discussion in a multidisciplinary oncological board\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Residual or recurrent esophageal lesions\n* Ulcerated esophageal lesions\n* Patients with severe cardiovascular, kidney or liver disease\n* History of hypersensitivity to hyaluronic acid\n* Pregnant or lactating women",{"count":79,"type":22},[203],"This is a randomized, single-center clinical trial that will compare the efficacy of two substances used in the submucosal cushion formation stage of endoscopic submucosal resections of early esophageal malignant neoplasms. Such substances are hyaluronic acid in the form of TS-905 Blue Eyeₒ and hydroxyethylamide (Voluven®).",[34,332,445],"Hyaluronic Acid",[34,332,445],{"date":427,"type":41},{"date":449,"type":41},"2023-06-19",{"date":451,"type":22},"2026-04-13",{"name":433,"class":137},{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":460,"targetDuration":462,"studyType":120,"phases":4,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":138},"100501059","the-australia-and-new-zealand-multicentre-upper-gastrointestinal-endoscopic-tissue-resection-study-100501059","NCT05804331","The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study","ANZ UGI","Inclusion Criteria:\n\n* UGI neoplastic lesions \\> 10mm\n\n  * Lesions for ESD limited to the mucosal and\u002For submucosal layer OR\n  * Lesions for EFTR limited to the muscularis propria layer OR\n  * Lesions for STER limited to the submucosal and\u002For muscularis propria layer\n* Aged 18 years or older\n\nExclusion Criteria:\n\n* Age less than 18\n* Unable to give informed consent\n* Pregnant or lactating patients\n* Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally",{"count":461,"type":22},500,"3 Years","To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions",[465,466,123,467,468,469,470,334,34],"Cancer of Stomach","Oesophageal Cancer","Gastric Adenocarcinoma","GI Cancer","GIST","Neuroendocrine Tumors","2025-03-25",{"date":473,"type":41},"2025-03-27",{"date":475,"type":41},"2023-03-14",{"date":477,"type":22},"2028-09-14",{"name":479,"class":137},"Western Sydney Local Health District",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":206,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":508},"100565554","phase-2-tranilast-vs-steroids-to-prevent-esophageal-stricture-tapes-after-endoscopic-resection-for-superficial-neoplasms-100565554","NCT06643689","Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) After Endoscopic Resection for Superficial Neoplasms","Tranilast Vs. Steroids to Prevent Esophageal Stricture (TAPES) Following Circumferential Endoscopic Submucosal Dissection (cESD) for Superficial Neoplasms","TAPES","Inclusion Criteria:\n\n1. age\\>18 and proficient in Mandarin.\n2. underwent cESD treatment for superficial esophageal neoplasms.\n3. agree to sign an informed consent form.\n\nExclusion Criteria:\n\n1. allergic to tranilast.\n2. with severe comorbid conditions.\n3. pregnant or breastfeeding.",{"count":489,"type":22},394,[90],"The goal of this clinical trial is to learn if tranilast works to prevent esophageal stricture after circumferential endoscopic submucosal dissection (cESD) in adults. It will also help us learn more about the safety of tranilast. The main questions it aims to answer are: 1. Does tranilast reduce the occurence of esophageal stricture in participants after cESD? 2. What medical problems do participants have when taking tranilast.\n\nResearchers will compare tranilast to prednisone (a steroid used in clinical practice with potential defects) to see if tranilast works well to prevent esophageal stricture.\n\nParticipants will: 1. Take tranilast or prednisone every day for 8 weeks. 2. Attend visit (at clinic or phone) once every 2 weeks for checkups and tests until 16 weeks. 3. Keep a diary of their symptoms and let researchers know during the 16 weeks follow up.",[493,34],"Esophageal Stricture",[495,34,496,497,498],"Tranilast","Steroids","Esophageal stricture","Circumferential Endoscopic Submucosal Dissection","2024-11-12",{"date":501,"type":41},"2024-11-14",{"date":503,"type":22},"2025-01-01",{"date":505,"type":22},"2028-12-31",{"name":507,"class":137},"Second Affiliated Hospital, School of Medicine, Zhejiang University",3,{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":23,"phases":519,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":138},"100565777","phase-2-fruquintinib-in-combination-with-tislelizumab-followed-by-radiotherapy-in-esophageal-squamous-cell-carcinoma-100565777","NCT06646588","Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma","Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Relapsed or Progressive Esophageal Squamous Cell Carcinoma","SJZ-RMEEC01","Inclusion Criteria:\n\n* Voluntary participation and written signed informed consent;\n* Age ≥ 18 years old, gender is not limited;\n* Histologically or cytologically confirmed limited-stage small cell lung cancer (2009 AJCC\u002FUICC\u002FIASLC lung cancer TNM staging criteria, limited-stage SCLC is any T stage, any N stage, and M0), and patients with suspected brain or bone metastasis at the time of screening should undergo brain MRI or ECT before study enrollment;\n* There are immunohistochemical results;\n* Chemotherapy must include either cisplatin or carboplatin, in combination with etoposide;\n* Physical status score ECOG 0-1;\n* Weight \\> 40 kg;\n* Expected survival ≥ 6 months;\n* According to RECIST 1.1 guidelines, at least one lesion (not previously receiving radiotherapy) with a maximum diameter ≥ 10 mm as accurately measured by computed tomography (CT) or magnetic resonance imaging (MRI) at baseline (except lymph nodes, whose short axis must be ≥ 15 mm); And the lesion is suitable for repeated accurate measurement.;\n* No previous immunotherapy;\n* no serious abnormalities of haematopoietic, cardiac, pulmonary, hepatic; and renal functions and immunodeficiency (Haematology: white blood cells ≥3.5×109\u002FL; neutrophils ≥1.5×109\u002FL; haemoglobin ≥90g\u002FL; platelets\n\n  ≥100×109\u002FL. Liver and kidney function: total bilirubin ≤1.5 times the upper limit of normal (ULN); AST (SGOT) and ALT (SGPT) ≤2.5 times the upper limit of normal; creatinine ≤1.5 times the upper limit of normal; albumin ≥30 g\u002FL. Coagulation: International Normalised Ratio (INR) or Prothrombin Time (PT) or Activated Partial Thromboplastin Time (APTT)\n\n  ≤ 1.5 times ULN; if the subject is receiving anticoagulation therapy, PT or INR is acceptable as long as the PT or INR is within the range of the anticoagulant drug formulation. Echocardiographic assessment: left ventricular ejection fraction (LVEF) ≥ low limit of normal (50%). Pulmonary function FEV1 ≥70% of % of predicted value and DLCO ≥60% of % of predicted value).\n* The female patient has evidence of postmenopausal status, or the urine or serum pregnancy test results of the premenopausal woman are negative. Women who stop menstruating for 12 months without other medical reasons are considered menopausal.\n\nExclusion Criteria:\n\n* Distant organ metastases (excluding supraclavicular lymph nodes) as determined by CT evaluation during screening and prior imaging;\n* have received prior radiotherapy to the chest;\n* have medical contraindications to etoposide - platinum (carboplatin or cisplatin) based chemotherapy;\n* having any active autoimmune disease or a history of autoimmune disease (e.g. interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary gland inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (which can be included if hormone replacement therapy is effective), etc.), and a history of immunosuppressive drug use within 28 days, with the exception of the use of hormones for the purpose of dealing with toxicity from radiotherapy;\n* Previously received or are receiving other PD-1 antibody therapy or other immunotherapy targeting PD-1\u002FPD-L1, or are currently participating in other interventional clinical studies for treatment;\n* Have received other anti-tumour therapy (including herbal therapy with anti-tumour effect) within 4 weeks prior to the first dose of the study; have received long-term systemic immunotherapy or hormone therapy (except physiological replacement therapy, e.g., oral thyroxine for hypothyroidism) within 4 weeks prior to the first dose of the study; and have been treated with other experimental drugs or interventional clinical studies within 4 weeks prior to the first dose of the study;\n* Patients with uncontrolled clinical cardiac symptoms or disease such as\n\n  (1) NYHA class II or higher heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, and (4) clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;\n* with congenital or acquired immune function defects (e.g., HIV-infected patients), active hepatitis B (HBV-DNA ≥104 copies\u002Fml) or hepatitis C (hepatitis C antibody-positive with HCV-RNA above the lower limit of detection of the analytical method), or active tuberculosis;\n* Have an active infection or unexplained fever \\>38.5°C within 2 weeks prior to screening (at the investigator's discretion, subjects may be enrolled for fever arising from tumours);\n* In the judgement of the investigator, the subject has other factors that may cause him\u002Fher to be forced to terminate the study in the middle of the study, e.g., suffering from other serious illnesses (including psychiatric illnesses) that require comorbid treatment, family or social factors that may affect the safety of the subject or the collection of trial data.",{"count":518,"type":22},67,[90],"According to the Global Burden of Disease Study, the number of esophageal cancer cases globally increased from 319,969 in 1990 to 534,563 in 2019, a relative increase of 67.07 per cent. In addition, GLOBOCAN 2020 reported that the global incidence of esophageal cancer climbed to 604,100, accounting for 3.1% of all tumor sites and ranking 7th out of 36 cancers. In addition, the number of global deaths from esophageal cancer increased from 319,332 in 1990 to 498,067 in 2019, a relative increase of 55.97%.GLOBOCAN 2020 reported about 544,076 new esophageal cancer deaths, which accounted for 5.5% of all study centres and ranked 6th among 36 cancers. Chemotherapy is the standard of care for advanced esophageal squamous cell carcinoma, but conventional chemotherapy has limited efficacy, and studies have shown lower median overall survival with chemotherapy in patients with advanced esophageal cancer compared to patients with other stages. In recent years, with the first-line approval of immune checkpoint inhibitors, the treatment of esophageal cancer has entered the immune era. Immune checkpoint inhibitors have become an important therapeutic option for patients with advanced esophageal cancer who have failed chemotherapy. This study will explore the efficacy and safety of this small molecule anti-angiogenic drug, fruquintinib, in combination with tislelizumab in esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors.",[34],"2024-10-15",{"date":524,"type":41},"2024-10-17",{"date":526,"type":41},"2024-04-01",{"date":528,"type":22},"2027-04-30",{"name":530,"class":137},"Hebei Medical University Fourth Hospital",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":358,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":539,"conditions":540,"keywords":541,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":138},"100492133","barretts-esophagus-and-esophageal-adenocarcinoma-searching-for-reliable-diagnostic-rna-plasma-based-biomarkers-100492133","NCT05688176","Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers","Liquid Biopsies in Esophageal Adenocarcinoma: Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers","Inclusion Criteria:\n\n* Barrett's Esophagus with length \\> 3cm OR esophageal adenocarcinoma histologically proven\n* Adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent\n* Age over 18 years\n* No other concurrent malignant disease\n* No inclusion in other clinical trials interfering with the study protocol\n* No concurrent chronic systemic immune or hormone therapy, except neoadjuvant chemotherapy\n* Absence of any severe organ insufficiency\n* No pregnancy or breast feeding\n* Written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breast feeding\n* Active bacterial, viral or fungal infection\n* Parenchymal liver disease (any stage cirrhosis)\n* High risk of bleeding during biopsy (anticoagulants, esophageal varices)\n* Esophageal squamous cell carcinoma\n* Helicobacter pylori positive at the time of biopsy sampling\n* Radiofrequency ablation of the oesophagus\n* Psychiatric pathology capable of affecting comprehension and judgement faculty",{"count":118,"type":22},"This study is designed to perform a explorative search of the transcriptome to detect new circulating diagnostic sensitive and specific biomarkers in patients with Barrett's esophagus or esophageal adenocarcinoma.",[34],[34,542,543],"Liquid biopsy","Transcriptome","2024-07-16",{"date":546,"type":41},"2024-07-17",{"date":548,"type":4},"2016-06",{"date":550,"type":22},"2027-01-31",{"name":552,"class":137},"University Hospital, Ghent",{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":558,"acronym":4,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":23,"phases":562,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":138},"100522733","phase-3-pd-1-inhibitor-plus-chemotherapy-with-or-without-radiotherapy-in-patients-with-metastatic-esophageal-cancer-100522733","NCT06086457","PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer","PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer: A Randomized Multicenter Phase III Trial","Inclusion Criteria:\n\n* 1\\. ≥18 years, any gender\n* 2\\. Histologically or cytologically confirmed squamous cell carcinoma of esophageal cancer. The initial clinical stage is IVb (2018 American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 8th Edition) , with distant metastasis involving no more than 2 organs (lymph node metastasis is counted);\n* 3\\. ECOG (Eastern Cooperative Oncology Groupper) formance status \\\u003C= 1. Patients aged 65 years and over need to complete G8 screening or Comprehensive Geriatric Assessment, and the final evaluation is good;\n* 4.There was no significant abnormality in laboratory routine indicators such as blood routine and liver and kidney function;\n* 5.No prior history of thoracic radiation;\n* 6.Expected survival is more than 12 weeks;\n* 7.Informed consent provided.\n\nExclusion Criteria:\n\n* 1.Patients with other cancer history except hypopharyngeal carcinoma in situ, non-malignant skin cancer and cervical carcinoma in situ.\n* 2.Received surgery (except ostomy), chemotherapy or other anti-tumor treatment before enrollment；\n* 3\\. Active infection currently exists . The following conditions occurred within 6 months before randomization: myocardial infarction, cerebrovascular accident, or received gastrointestinal, neurological, cardiopulmonary surgery;\n* 4\\. History of allergy to chemotherapy drugs or autoimmune disease;\n* 5\\. Participate in other clinical trials at present or within 4 weeks before enrollment;\n* 6.There are factors such as high risk of fistula that radiotherapy cannot be safely carried out as assessed by the radiation oncologist.",{"count":561,"type":22},436,[563],"PHASE3","The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently.\n\nOn this basis, the investigators intend to conduct a prospective, multicenter phase III clinical trial to assess whether radiotherapy with concurrent chemotherapy and immunotherapy could further improve the survival of patients with metastatic esophageal cancer.\n\nAccompanied tissue samples, blood samples and urine samples will be analyzed by molecular biological detection (Including Whole Exome Sequencing and proteomics) to explore potential biomarkers for predicting outcomes, efficacy and toxicity.",[34],[567,568],"Radiotherapy","PD-1 inhibitor","2024-07-12",{"date":544,"type":41},{"date":572,"type":41},"2024-02-04",{"date":574,"type":22},"2029-08-28",{"name":576,"class":137},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":585,"targetDuration":4,"studyType":120,"phases":4,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":590,"lastUpdatePostDateStruct":591,"startDateStruct":593,"completionDateStruct":595,"leadSponsor":597,"locationsCount":599},"100412778","metachronic-brain-metastases-after-esophagectomy-for-esophageal-cancer-metabrec-100412778","NCT04654975","Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)","Risk Factors and Treatment Options for Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer: a Multicentric Retrospective Cohort Study (METABREC)","METABREC","Inclusion Criteria:\n\n* Patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and 31 december 2019\n* All types of neoadjuvant treatment followed by surgery, primary surgery or salvage surgery.\n* Adenocarcinoma or squamous cell carcinoma histology\n\nExclusion Criteria:\n\n* other histology type than adenocarcinoma or squamous cell carcinoma\n* Hypopharyngeal carcinoma extending to the esophagus (requiring total laryngo-pharyngo-esophagectomy)\n* Early esophageal carcinoma (cT IS-1a N0 M0)\n* palliative esophagectomy",{"count":586,"type":22},10000,"Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured: mostly those with recurrence in one single organ.\n\nBrain metastases are rare after esophagectomy for cancer, but they have a serious impact on survival. Agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier.\n\nThere is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes. However, this is not clear yet. A potential explanation could be that chemotherapy disturbs the blood-brain-barrier, hereby facilitating the migration of tumor cells to the brain.\n\nThe purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer. Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio for brain metastases (comparison between primary surgery and neoadjuvant treatment followed by surgery), time to recurrence and risk factors, number and characteristics of the brain metastases.",[34,231,589],"Brain Metastases","2024-07-02",{"date":592,"type":41},"2024-07-03",{"date":594,"type":41},"2020-06-02",{"date":596,"type":22},"2025-03-31",{"name":598,"class":137},"Universitaire Ziekenhuizen KU Leuven",8,{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":604,"acronym":605,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":607,"targetDuration":609,"studyType":120,"phases":4,"briefSummary":610,"conditions":611,"keywords":613,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":624},"100302879","distribution-of-lymph-node-metastases-in-esophageal-carcinoma-100302879","NCT03222895","Distribution of Lymph Node Metastases in Esophageal Carcinoma","TIGER","Inclusion Criteria:\n\n* Primary squamous cell or adenocarcinoma of the esophagus or esophago-gastric junction\n* Surgically resectable (cT1-4a, N0-3, M0)\n* Adequate physical condition to undergo transthoracic surgery (ASA 1-3)\n* Transthoracic esophagectomy\n\nExclusion Criteria:\n\n* Previous thoracic or abdominal (upper GI) surgery disturbing lymph drainage of the esophagus and stomach\n* Patients with in situ carcinoma or high grade dysplasia",{"count":608,"type":22},5000,"5 Years","Background: Lymph node status is an important prognostic parameter in esophageal carcinoma and an independent predictor of survival. Distribution of metastatic lymph nodes may vary with tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy. Surgical strategy depends on the distribution pattern of nodal metastases but consensus on the extent of lymphadenectomy differs worldwide. Especially for adenocarcinoma the distribution of lymph node metastases has not yet been described in large series. Aim of the present study is to evaluate the distribution of lymph node metastases in esophageal carcinoma specimens following transthoracic esophagectomy with at least a 2-field lymphadenectomy.\n\nMethods: The TIGER-study is a multinational observational cohort study. All patients with a resectable esophageal or gastro-esophageal junction carcinoma in whom a transthoracic esophagectomy with a 2- or 3-field lymphadenectomy is performed in participating centers will be included. All lymph node stations will be excised and separately sent for pathological examination. Cluster analysis will be performed to identify patterns of metastases in relation to tumor location, tumor histology, tumor invasion depth and neoadjuvant therapy.\n\nConclusion: TIGER will provide a roadmap of the location of lymph node metastases in relation to tumor histology, tumor location, invasion depth, number of lymph nodes and lymph node metastases, pre-operative diagnostics, neo-adjuvant therapy and survival. Patient-tailored treatment can be developed on the basis of these results, such as the the optimal radiation field and extent of lymphadenectomy based on the primary tumor characteristics.",[34,612],"Lymph Node Metastases",[34,614,231],"Lymph node metastases","2024-02-12",{"date":617,"type":41},"2024-02-13",{"date":619,"type":41},"2019-03-01",{"date":621,"type":22},"2028-06-01",{"name":623,"class":137},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",19,{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":200,"enrollmentInfo":632,"targetDuration":4,"studyType":23,"phases":634,"briefSummary":635,"conditions":636,"keywords":639,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":650,"locationsCount":138},"100487209","phase-2-camrelizumab-combined-with-chemoradiotherapy-in-advanced-esophageal-cancer-100487209","NCT05624099","Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.","Prospective Single-arm, Exploratory, Multicenter Phase II Clinical Study of Camrelizumab Combined With Chemoradiotherapy in the Treatment of Advanced First-line Esophageal Phosphorous Carcinoma","Inclusion Criteria:\n\n1. Sign written informed consent and voluntarily participate in this study;\n2. Patients with esophageal squamous cell carcinoma confirmed by histopathology and\u002For immunohistochemistry (8th edition 2017) had UICC\u002FAJCC TNM stage IVA or oligometastatic stage IVB;\n3. Survival is expected to exceed 3 months\n4. Age 18-75;\n5. ECOG PS 0-2\n6. Never received any systemic anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, targeted and immunotherapy;\n7. Have at least one measurable lesion\n8. Normal function of major organs, including:\n\n   1. Routine blood test (no blood components, cell growth factors, whitening drugs, platelet raising drugs, and anemia correcting drugs are allowed within 14 days before the first use of study drugs)\n\n      White blood cell count ≥ 3.0×10\\^9\u002FL\n\n      Neutrophil count ≥ 1.0×10\\^9\u002FL\n\n      Platelet count ≥ 80×109\u002FL\n\n      Hemoglobin ≥ 80 g\u002FL\n   2. Blood biochemical examination:\n\n   Total bilirubin ≤ 1.5×ULN\n\n   ALT ≤2.5×ULN, AST ≤2.5×ULN,\n\n   Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 45mL\u002Fmin\n9. Subjects have good compliance and cooperate with follow-up\n\nExclusion Criteria:\n\n1. The presence of uncontrollable pleural effusion, pericardial effusion or ascites that require repeated drainage;\n2. Poor nutritional status, BMI \\\u003C 18.5 Kg\u002Fm\\^2; If symptomatic nutritional support was corrected before randomization, enrollment could be considered after evaluation by the principal investigator;\n3. Gastrointestinal bleeding (bleeding volume \\> 200ml\u002F day);\n4. Patients with deep ulcers as determined by the investigator;\n5. Previous allergy to monoclonal antibodies, any component of camrelizumab, paclitaxel, cisplatin or other platinum-based drugs;\n6. Has received or is receiving any of the following medical treatment:\n\n   1. any radiation, chemotherapy or other antitumor drugs for the tumor;\n   2. Being treated with immunosuppressive agents or systemic hormones for immunosuppression purposes (dose \\>10mg\u002F day prednisone or equivalent) within 2 weeks prior to the first use of the study drug; In the absence of active autoimmune disease, inhaled or topical steroids and adrenocorticosteroid replacement at a dose of \\>10mg\u002F day or its equivalent are permitted;\n   3. Received live attenuated vaccine within 4 weeks before the first administration of the study drug;\n   4. Major surgery or severe trauma within 4 weeks before the first use of the study drug;\n7. A history of any active autoimmune disease or autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (which may be considered for inclusion after hormone replacement therapy); Patients with complete remission of psoriasis or childhood asthma\u002Fallergies who did not require any intervention as adults were considered for inclusion, but patients requiring medical intervention with bronchodilators were not included;\n8. A history of immunodeficiency, including being HIV positive, or suffering from another acquired or congenital immunodeficiency disease, or a history of organ transplantation or allogeneic bone marrow transplantation;\n9. The presence of poorly controlled cardiac clinical symptoms or diseases, including but not limited to:\n\n   Such as (1) NYHAII grade or above heart failure; (2) unstable angina pectoris; (3) myocardial infarction occurred within 1 year; (4) Clinically significant supraventricular or ventricular arrhythmias are not well controlled without clinical intervention or after clinical intervention;\n10. Severe infection (CTCAE \\> 2) occurred within 4 weeks before the first use of the study drug, such as severe pneumonia, bacteremia, infection complications requiring hospitalization; Baseline chest imaging examination indicated active pulmonary inflammation, signs and symptoms of infection within 14 days before the first use of study drugs, or the need for oral or intravenous antibiotic treatment, except for prophylactic antibiotic use;\n11. Patients with active pulmonary tuberculosis infection found by medical history or CT examination, or with a history of active pulmonary tuberculosis infection within 1 year before enrollment, or with a history of active pulmonary tuberculosis infection more than 1 year ago but without regular treatment;\n12. The presence of active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 104 copies\u002FmL) and hepatitis C (HCV antibody positive and HCV RNA above the assay limit);\n13. In the judgment of the investigator, there are other factors that may lead to the forced termination of the study, such as the presence of other serious medical conditions (including mental illness) requiring concomitant treatment, alcoholism, substance abuse, family or social factors, and factors that may affect the safety or compliance of the subjects.",{"count":633,"type":22},75,[90],"This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.",[34,637,638],"Esophageal Diseases","Digestive System Neoplasms",[640,641,642,643],"Immunotherapy","Platinum","radiotherapy","Paclitaxel","2023-10-17",{"date":646,"type":41},"2023-10-19",{"date":648,"type":41},"2023-08-01",{"date":134,"type":22},{"name":651,"class":273},"Fujian Cancer Hospital",{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":358,"sex":18,"minAge":19,"maxAge":200,"enrollmentInfo":659,"targetDuration":4,"studyType":23,"phases":660,"briefSummary":661,"conditions":662,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":670,"locationsCount":138},"100500730","effect-of-nst-whole-course-nutritional-management-on-nutritional-status-and-adverse-reactions-in-esophageal-cancer-100500730","NCT05800054","Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer","Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy","Inclusion Criteria:\n\n* Sign the informed consent; must have good compliance with the treatment plan and follow-up.\n* No gender restriction, but age between 18 and 75 years old;\n* Cytological or histological is confirmed esophageal squamous cell carcinoma;\n* Non-surgical treatment of stage II-III primary esophageal cancer (except biopsy);\n* The primary tumor can be evaluated;\n* No distant organ metastasis;\n* PG-SGA score B (2\\~8) or C (≥9);\n* KPS score ≥ 70 points, ECOG physical condition score 0-1 points;\n* The function of major organs (bone marrow, liver, kidney function) 7 days before treatment, meet the following criteria: Blood routine examination standards (without blood transfusion within 14 days):\n\n  * Hemoglobin (HB) ≥ 100g\u002FL;\n\n    * White blood cells (WBC) ≥ 4×109\u002FL; Absolute neutrophil count (ANC) ≥1.5×109\u002FL;\n\n      * Platelet (PLT) ≥ 100×109\u002FL.\n* The biochemical examination shall meet the following standards:\n\n  * Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);\n\n    * Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 1.5 times ULN;\n\n      * Serum creatinine (Cr) ≤ 1.5 times ULN or creatinine clearance rate (CCr) ≥ 60ml\u002Fmin.\n* Expected survival ≥ 6 months.\n\nExclusion Criteria:\n\n* No malnutrition or nutritional risk; PG-SGA score of A;\n* Severely impaired intestinal function, or intolerance of enteral nutrition;\n* Severe vomiting, gastrointestinal bleeding, intestinal obstruction;\n* Patients with very severe malnutrition cannot tolerate radiotherapy and chemotherapy;\n* The primary tumor or lymph node has received radiotherapy, chemotherapy or targeted therapy;\n* Suffering from other malignant tumors within 5 years (except for completely cured cervical carcinoma in situ or skin basal cell carcinoma);\n* Subjects who have received other drug trials within the past month;\n* Those with severe allergic history or idiosyncratic constitution;\n* Those with a history of severe lung or heart disease;\n* Serious comorbidities, such as uncontrolled hypertension, heart failure, etc.;\n* Pregnant or breastfeeding women;\n* Currently or planning to participate in other clinical trials;\n* Refusal or inability to sign the informed consent form to accept participation in the trial.",{"count":147,"type":22},[203],"This study is a randomized, open, parallel controlled clinical trial. The main purpose of this study was to compare the changes in body weight\u002Fbody mass index (BMI) before and after treatment between the two groups of patients with NST full-course nutritional management and without NST full-course nutritional management.\n\nThe secondary objective was to compare the quality of life, nutritional status, immune function and inflammatory response, adverse reactions of radiotherapy and chemotherapy, and short-term\u002Flong-term efficacy between the two groups.\n\nThe treatment plan was: esophageal cancer with routine nutrition guidance as the control group, and the NST whole-process intervention guidance as the experimental group.\n\n1\\. Experimental group: NST whole-course intervention\n\n1. Nutritionists formulate nutritional programs and manage them in a refined manner. On the basis of the patient's natural diet (food and homogenate meal), enteral nutritional preparations or parenteral nutritional supplements are given according to the patient's gastrointestinal obstruction, dietary structure, and food intake. Energy 30-35kcal\u002Fkg\u002Fd, protein 1.2-1.5g\u002Fkg\u002Fd. Enteral nutrition administration route: oral or tube feeding or ostomy, oral feeding is preferred; severe obstruction of eating or oral can not meet the target nutrition, choose tube feeding or ostomy. When it is expected that enteral nutrition cannot meet 60% of the target energy requirement for 3 to 5 days, choose parenteral nutrition. The enteral nutritional preparation adopts the whole protein enteral nutritional preparation Nengquan, and\u002For the tumor nutritional preparation Ruineng, and\u002For whey protein powder.\n2. Radiotherapy\n3. Chemotherapy 2. Control group: routine nutrition guidance for esophageal cancer\n\n(1) Nutritional therapy: The nutritional program was the same as that of the experimental group, and the patients performed it themselves.\n\n(2) Concurrent chemoradiotherapy: the same as the experimental group.\n\nEfficacy evaluation:\n\n1. Body weight and body mass index (BMI)\n2. Quality of life score (EORTCQLQ-C30)\n3. Nutritional status\n4. Immune function and inflammatory response (total lymphocytes, CRP, IL-6)\n\n(4) Intestinal mucosal barrier and intestinal flora (5) Adverse reactions of radiotherapy and chemotherapy (6) Short-term\u002Flong-term efficacy (5) Evaluation of treatment side effects (6) Short-term\u002Flong-term efficacy",[34,663],"Adverse Drug Event","2023-03-23",{"date":666,"type":41},"2023-04-05",{"date":668,"type":41},"2021-01-01",{"date":134,"type":22},{"name":671,"class":137},"The First Affiliated Hospital with Nanjing Medical University"]